There's isolated incidents of companies (warning) because of patent expiration or pipeline problems or both, but they are very isolated.

Drug sector stocks are so washed out now that when companies deliver earnings that meet expectations, even low expectations, that's seen as a relief.

Warner-Lambert is trying to maximize the price paid for the company. They think that they are entitled to a higher price, and this facilitates that.

Lilly to us is going to emerge as the drug company of the decade.